Takeda Builds On Vaccines With Inviragen Acquisition
This article was originally published in The Pink Sheet Daily
The Japanese pharma will pay $35 million to acquire the private vaccines maker, which has a dengue vaccine in Phase II development. Takeda has made vaccines a priority and has been actively building the business through acquisitions.
You may also be interested in...
A new evaluation route that the European Medicines Agency launched last year came at the right time for Takeda’s dengue vaccine candidate.
It’s early days in the launch of Zurzuvae for postpartum depression, but Sage highlighted encouraging prescription trends during the company’s fourth quarter sales and earnings call.
The company is looking to spend some of the cash it earned on the sale of Telavant on new assets that will join the late-stage pipeline.